MedTrace Logo

The Effect of Neu-P11 on Symptoms in Patients With D-IBS

NCT01558284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2014-02-05

No results posted yet for this study

Summary

Placebo controlled double-blind study with 40 patients who have an diarrhea-predominant IBS, 20 get Neu-P11, 20 get a placebo. Neu-P11 is a, Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist.

Conditions

  • Diarrhea- Irritable Bowel Syndrome

Interventions

DRUG

Neu-P11

Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Martin Storr, Prof Dr. · Medizinische Klinik 2 LMU Muenchen

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-01-31
Completion
2014-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01558284 on ClinicalTrials.gov